Plaque Psoriasis — Safety and Efficacy Study of CF101 to Treat Psoriasis
Citation(s)
A Phase 2, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled Study of the Safety and Activity of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis